Skip to main content

Table 3 Univariate analysis of clinicopathological variables for PFS after lanreotide therapy

From: Tumour-to-liver ratio determined by [68Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours

VariableHazard ratio (95% CI)p value
EGOG performance status (1 vs. 0)3.749 (1.084–12.965)0.037*
Primary tumour site (pancreas vs. other)0.864 (0.0.356–2.097)0.746
NET WHO grade (2 and 3 vs. 1)1.833 (0.611–5.499)0.279
Presence of carcinoid symptoms (yes vs. no)0.616 (0.203–1.868)0.392
Previous surgery (yes vs. no)0.720 (0.290–1.789)0.480
Previous chemotherapy (yes vs. no)0.947 (0.217–4.133)0.942
Lanreotide dose (90 mg vs. 120 mg)2.030 (0.464–8.888)0.347
Hepatic tumour volume assessed by CT/MRI (> 25% vs. 0–25%)0.466 (0.170–1.275)0.137
  1. CI confidence interval
  2. *Statistically significant (p < 0.05)